Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper.
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H. Matsumoto H, et al. Among authors: takahashi s. Int J Urol. 2020 May;27(5):362-368. doi: 10.1111/iju.14210. Epub 2020 Mar 14. Int J Urol. 2020. PMID: 32172529
Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision.
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H. Matsumoto H, et al. Among authors: takahashi s. Int J Urol. 2020 Sep;27(9):702-709. doi: 10.1111/iju.14281. Epub 2020 Jun 21. Int J Urol. 2020. PMID: 32564429
Japanese clinical practice guidelines for prostate cancer 2023.
Kohjimoto Y, Uemura H, Yoshida M, Hinotsu S, Takahashi S, Takeuchi T, Suzuki K, Shinmoto H, Tamada T, Inoue T, Sugimoto M, Takenaka A, Habuchi T, Ishikawa H, Mizowaki T, Saito S, Miyake H, Matsubara N, Nonomura N, Sakai H, Ito A, Ukimura O, Matsuyama H, Hara I. Kohjimoto Y, et al. Among authors: takahashi s. Int J Urol. 2024 Nov;31(11):1180-1222. doi: 10.1111/iju.15545. Epub 2024 Jul 30. Int J Urol. 2024. PMID: 39078210
Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.
Nakajima K, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A; PROSTAT-BSI Investigators. Nakajima K, et al. Among authors: takahashi s. Int J Urol. 2018 May;25(5):492-499. doi: 10.1111/iju.13556. Epub 2018 Apr 6. Int J Urol. 2018. PMID: 29633398
Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
Nakajima K, Mizokami A, Matsuyama H, Ichikawa T, Kaneko G, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A; PROSTAT-BSI Investigators. Nakajima K, et al. Among authors: takahashi s. Int J Urol. 2021 Sep;28(9):955-963. doi: 10.1111/iju.14614. Epub 2021 Jun 19. Int J Urol. 2021. PMID: 34148264 Free PMC article.
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
Kamijima T, Yaegashi H, Mizokami A, Nakajima K, Matsuyama H, Ichikawa T, Nishimoto K, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Enokida H. Kamijima T, et al. Among authors: takahashi s. Anticancer Res. 2022 Jun;42(6):3099-3108. doi: 10.21873/anticanres.15798. Anticancer Res. 2022. PMID: 35641302
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Eto M, Uemura H, Tomita Y, Kanayama H, Shinohara N, Kamei Y, Fujii Y, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group. Eto M, et al. Cancer Sci. 2014 Dec;105(12):1576-83. doi: 10.1111/cas.12546. Epub 2014 Nov 25. Cancer Sci. 2014. PMID: 25283266 Free PMC article. Clinical Trial.
11,410 results
You have reached the last available page of results. Please see the User Guide for more information.